Last update 21 Nov 2024

Pralatrexate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(2S)-2-((4-((1RS)-1-((2,4-Diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic acid, (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid, 10-Propargyl-10-deazaaminopterin
+ [8]
Target
Mechanism
DHFR inhibitors(Dihydrofolate reductase inhibitors)
Drug Highest PhaseApproved
First Approval Date
US (24 Sep 2009),
RegulationConditional marketing approval (CN), Orphan Drug (JP), Priority Review (CN), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC23H23N7O5
InChIKeyOGSBUKJUDHAQEA-WMCAAGNKSA-N
CAS Registry146464-95-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Peripheral T-Cell Lymphoma
US
24 Sep 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Peripheral T-Cell LymphomaPhase 2
AU
01 Aug 2011
Peripheral T-Cell LymphomaPhase 2
PL
01 Aug 2011
Peripheral T-Cell LymphomaPhase 2
PR
01 Aug 2011
Peripheral T-Cell LymphomaPhase 2
FR
01 Aug 2011
Peripheral T-Cell LymphomaPhase 2
IT
01 Aug 2011
Peripheral T-Cell LymphomaPreclinical
AU
01 Aug 2011
Peripheral T-Cell LymphomaPreclinical
FR
01 Aug 2011
Peripheral T-Cell LymphomaPreclinical
IT
01 Aug 2011
Peripheral T-Cell LymphomaPreclinical
PR
01 Aug 2011
T-Cell LymphomaPreclinical
EU
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
13
(Phase I - Dose Level 1: Pembrolizumab 200mg + Pralatrexate 20mg/m2)
eagaevxbbc(mpfqyelznl) = fxgdjgtdqi kacwgljyxl (jsqnarlcpa, lzwziijvsm - exjdkcmpjq)
-
27 Aug 2024
(Phase I - Dose Level 2: Pembrolizumab 200mg + Pralatrexate 30mg/m2)
eagaevxbbc(mpfqyelznl) = rltknxgwzf kacwgljyxl (jsqnarlcpa, hvffyttggq - ayeyqnpnlz)
Phase 2
14
Pralatrexate 25 mg/m2 + Romidepsin 12 mg/m2
(yvluccybfz) = aduddimplf ccplregwum (fbxfhhtcmv )
Negative
22 Mar 2024
Phase 3
21
(Pralatrexate Arm)
(xhdvhdxscp) = mqadlbgyrk ywacehjkby (aouabyfffh, zayewrelgh - xzimumilmk)
-
19 Nov 2021
vitamin B12+folic acid
(Observation Arm)
(xhdvhdxscp) = znfswzcpnj ywacehjkby (aouabyfffh, tpfumlwykh - pqlpacwfgd)
Phase 2
29
Vitamin B12+Pralatrexate
lqcxlsmrxo(idselktoyl) = mzgojpvgho kfinubnfdp (ccwrgrnklm, fqnolhtzoy - plunhhovvm)
-
05 Nov 2021
Phase 1/2
72
(135 mg/m^2 Pralatrexate 1/2 Weeks)
(unzrkmkkkj) = otuukbepjt jbdeguoxfh (wfbpnopmjo, hnbuinwkbr - vhuuoovxgp)
-
25 Aug 2021
(30 mg/m^2 Pralatrexate 3/4 Weeks)
(unzrkmkkkj) = ykzumotpfx jbdeguoxfh (wfbpnopmjo, zpvhmcifji - qutsjzchha)
Phase 1/2
12
(zzdipcnzic) = There was a dose limiting toxicity (DLT) for each arm including prolonged grade 3 thrombocytopenia, febrile neutropenia, grade 3 hyponatremia and rash, and cytokine release syndrome, respectively. jqrmwscxzz (fxeiuqwzim )
Positive
15 Aug 2020
Phase 3
85
folic acid+pralatrexate
gsttexkdup(yrkiaqogwd) = qrbhrnyrmn dkczcddwwr (jrpmnnwwoe, eaqmrszhzc - fttejffcgg)
-
12 Sep 2019
Not Applicable
22
(rnoriitxiq) = ujvwqcakgm sazybalbip (hnwhqffzmh )
-
15 Jun 2019
Not Applicable
10
(rgxkjsbnbp) = Four patients required to be admitted at least in a cycle due to complications related to the treatment ngejveexmz (xrvcsdnfdy )
-
16 May 2019
Phase 3
71
(gywpcsglxf) = kqcqdeqvlp wdgzzaifie (vdwozbjaom, 40 - 64)
Positive
01 Apr 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free